
Dec 23 (Reuters) - Reviva Pharmaceuticals Holdings Inc RVPH.O:
REVIVA ANNOUNCES REGULATORY UPDATE REGARDING THE DEVELOPMENT OF BRILAROXAZINE FOR THE TREATMENT OF SCHIZOPHRENIA
REVIVA PHARMACEUTICALS HOLDINGS INC - FDA RECOMMENDS SECOND PHASE 3 TRIAL FOR BRILAROXAZINE
REVIVA PHARMACEUTICALS HOLDINGS INC - RECOVER-2 TRIAL PLANNED FOR H1 2026